These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 29566843)

  • 1. The Importance of Model Structure in the Cost-Effectiveness Analysis of Primary Care Interventions for the Management of Hypertension.
    Peñaloza-Ramos MC; Jowett S; Sutton AJ; McManus RJ; Barton P
    Value Health; 2018 Mar; 21(3):351-363. PubMed ID: 29566843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
    Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
    Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
    Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
    PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targets and self-management for the control of blood pressure in stroke and at risk groups (TASMIN-SR): protocol for a randomised controlled trial.
    O'Brien C; Bray EP; Bryan S; Greenfield SM; Haque MS; Hobbs FD; Jones MI; Jowett S; Kaambwa B; Little P; Mant J; Penaloza C; Schwartz C; Shackleford H; Varghese J; Williams B; McManus RJ
    BMC Cardiovasc Disord; 2013 Mar; 13():21. PubMed ID: 23522245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
    Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P
    Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential health impact and cost-effectiveness of drug therapy for prehypertension.
    Chen T; Yu D; Cornelius V; Qin R; Cai Y; Jiang Z; Zhao Z
    Int J Cardiol; 2017 Aug; 240():403-408. PubMed ID: 28501349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of different systolic blood pressure targets for people with a history of stroke or transient ischaemic attack: Economic analysis of the PAST-BP study.
    Penaloza-Ramos MC; Jowett S; Barton P; Roalfe A; Fletcher K; Taylor CJ; Hobbs FR; McManus RJ; Mant J
    Eur J Prev Cardiol; 2016 Oct; 23(15):1590-8. PubMed ID: 27226338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Telemonitoring and Self-Monitoring of Blood Pressure for Antihypertensive Titration in Primary Care (TASMINH4).
    Monahan M; Jowett S; Nickless A; Franssen M; Grant S; Greenfield S; Hobbs FDR; Hodgkinson J; Mant J; McManus RJ
    Hypertension; 2019 Jun; 73(6):1231-1239. PubMed ID: 31067190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects and cost-effectiveness of a guideline-oriented primary healthcare hypertension management program in Beijing, China: results from a 1-year controlled trial.
    Wang X; Li W; Li X; An N; Chen H; Jan S; Ming G; Hua Q; Yan X; Sun N; Zhao D; Wu Y
    Hypertens Res; 2013 Apr; 36(4):313-21. PubMed ID: 23154592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
    Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J
    J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension.
    Jönsson B; Hansson L; Stålhammar NO
    J Intern Med; 2003 Apr; 253(4):472-80. PubMed ID: 12653877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.
    Chowdhury EK; Reid CM; Zomer E; Kelly DJ; Liew D
    Am J Hypertens; 2018 Sep; 31(10):1156-1163. PubMed ID: 30010694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
    Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
    Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care.
    Mazzaglia G; Mantovani LG; Sturkenboom MC; Filippi A; Trifirò G; Cricelli C; Brignoli O; Caputi AP
    J Hypertens; 2005 Nov; 23(11):2093-100. PubMed ID: 16208153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Antihypertensive Therapy in Patients Older Than 80 Years: Cohort Study and Markov Model.
    Hazra NC; Rudisill C; Jackson SH; Gulliford MC
    Value Health; 2019 Dec; 22(12):1362-1369. PubMed ID: 31806192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. InnovaSEC in Action: Cost-effectiveness of Barostim in the Treatment of Refractory Hypertension in Spain.
    Soto M; Sampietro-Colom L; Sagarra J; Brugada-Terradellas J
    Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):563-71. PubMed ID: 26907729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Cost-Effectiveness of Hypertension Treatment in Non-Hispanic Blacks and Whites According to 2014 Guidelines: A Modeling Study.
    Vasudeva E; Moise N; Huang C; Mason A; Penko J; Goldman L; Coxson PG; Bibbins-Domingo K; Moran AE
    Am J Hypertens; 2016 Oct; 29(10):1195-205. PubMed ID: 27172970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.